The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Horizon scan of CAR-T for lymphoma
Sattva S Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the current lymphoma treatment landscape of CAR T-cell therapies in lymphoma and highlights its benefits, including long-term remissions. Dr Neelapu also explores unmet needs in this area, including the development of allogeneic off-the-shelf CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
